Brief Report: An Open-Label Study of the Neurosteroid Pregnenolone in Adults with Autism Spectrum Disorder
- 414 Downloads
The objective of this study was to assess the tolerability and efficacy of pregnenolone in reducing irritability in adults with autism spectrum disorder (ASD). This was a pilot, open-label, 12-week trial that included twelve subjects with a mean age of 22.5 ± 5.8 years. Two participants dropped out of the study due to reasons unrelated to adverse effects. Pregnenolone yielded a statistically significant improvement in the primary measure, Aberrant Behavior Checklist (ABC)-Irritability [from 17.4 ± 7.4 at baseline to 11.2 ± 7.0 at 12 weeks (p = 0.028)]. Secondary measures were not statistically significant with the exception of ABC-lethargy (p = 0.046) and total Short Sensory Profile score (p = 0.009). No significant vital sign changes occurred during this study. Pregnenolone was not associated with any severe side effects. Single episodes of tiredness, diarrhea and depressive affect that could be related to pregnenolone were reported. Overall, pregnenolone was modestly effective and well-tolerated in individuals with ASD.
KeywordsAutism spectrum disorder Pregnenolone Neurosteroids Irritability Open-label trial
This study was supported by a grant from the Escher Family Fund at the Silicon Valley Community Foundation to AYH and Mosbacher Fund to LKF. LKF is a recipient of the Ruth L. Kirschstein Individual Postdoctoral National Research Service Award. The authors would like to thank Pure Encapsulations (Sudbury, MA, USA) for donating the pregnenolone capsules.
Conflict of interest
Over the last 3 years, Dr. A.Y. Hardan has received research support and honorarium for consulting from the following companies: Bristol-Myers Squibb, Roche, Forest, and IntegraGen. Drs. L. K. Fung, J. Phillips, F. Haddad and Ms. R. A. Libove did not report any conflict.
- APA. (2013). Diagnostic and statistical manual of mental disorders: DSM-5 (4th ed.). Washington, DC: American Psychiatric Association.Google Scholar
- Fatemi, S. H., Reutiman, T. J., Folsom, T. D., Rooney, R. J., Patel, D. H., & Thuras, P. D. (2010). mRNA and protein levels for GABAAalpha4, alpha5, beta1 and GABABR1 receptors are altered in brains from subjects with autism. Journal of Autism and Developmental Disorders, 40, 743–750. doi:10.1007/s10803-009-0924-z.PubMedCrossRefPubMedCentralGoogle Scholar
- Fatemi, S. H., Reutiman, T. J., Folsom, T. D., Rustan, O. G., Rooney, R. J., & Thuras, P. D. (2014). Downregulation of GABA receptor protein subunits alpha6, beta2, delta, epsilon, gamma2, theta, and rho2 in superior frontal cortex of subjects with autism. Journal of Autism and Developmental Disorders,. doi:10.1007/s10803-014-2078-x.PubMedGoogle Scholar
- Kandel, E. R., Schwartz, J. H., Jessell, T. M., Siegelbaum, S. A., & Hudspeth, A. J. (2013). Principles of Neural Science (5th ed.). McGraw Hill Companies: New York.Google Scholar
- Kostakis, E., et al. (2013). The neuroactive steroid pregnenolone sulfate stimulates trafficking of functional N-methyl D-aspartate receptors to the cell surface via a noncanonical, G protein, and Ca2 + -dependent mechanism. Molecular Pharmacology, 84, 261–274. doi:10.1124/mol.113.085696.PubMedCrossRefPubMedCentralGoogle Scholar
- McDougle, C. J., et al. (1997). Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 685–693. doi:10.1097/00004583-199705000-00020.PubMedCrossRefGoogle Scholar
- Ritsner, M. S., et al. (2010). Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. Journal of Clinical Psychiatry, 71, 1351–1362. doi:10.4088/JCP.09m05031yel.PubMedCrossRefGoogle Scholar
- Sparrow, S., Balla, D. A., & Cinchetti, D. (2005). Vineland Adaptive Behavior Scales. Bloomington: IN, Pearson Education Inc.Google Scholar
- Sripada, R. K., Marx, C. E., King, A. P., Rampton, J. C., Ho, S. S., & Liberzon, I. (2013). Allopregnanolone elevations following pregnenolone administration are associated with enhanced activation of emotion regulation neurocircuits. Biological Psychiatry, 73, 1045–1053. doi:10.1016/j.biopsych.2012.12.008.PubMedCrossRefPubMedCentralGoogle Scholar
- Stigler, K. A., et al. (2009). Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger’s disorder: a 14-week, prospective, open-label study. Journal of Child and Adolescent Psychopharmacology, 19, 265–274. doi:10.1089/cap.2008.093.PubMedCrossRefPubMedCentralGoogle Scholar